New study confirms safety of liver fluke drug EGATEN

NCT ID NCT04230148

First seen Jan 04, 2026 · Last updated May 13, 2026 · Updated 15 times

Summary

This study tested the safety and effectiveness of the drug EGATEN (triclabendazole) in 301 people aged 6 and older with fascioliasis, a parasitic liver fluke infection. Participants received two doses of EGATEN 12 hours apart and were monitored for 90 days. The goal was to see if the drug safely cures the infection by clearing symptoms and improving lab results.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FASCIOLIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Medellín, Antioquia, 050010, Colombia

  • Novartis Investigative Site

    Alexandria, 21131, Egypt

  • Novartis Investigative Site

    Cairo, 11617, Egypt

  • Novartis Investigative Site

    San Martín de Porres, Lima region, 31, Peru

  • Novartis Investigative Site

    Cusco, 84, Peru

  • Novartis Investigative Site

    Istanbul, Fatih, 34093, Turkey (Türkiye)

  • Novartis Investigative Site

    Gaziantep, Sehitkamil, 27310, Turkey (Türkiye)

  • Novartis Investigative Site

    Sur, 21280, Turkey (Türkiye)

  • Novartis Investigative Site

    Van, 65080, Turkey (Türkiye)

  • Novartis Investigative Site

    Qui Nhon, Binh Dinh, 590000, Vietnam

Conditions

Explore the condition pages connected to this study.